Abstract
RNAi holds promise for neurodegenerative disorders caused by gain-of-function mutations. We and others have demonstrated proof-of-principle for viral-mediated RNAi in a mouse model of motor neuron disease. Lentivirus and adeno-associated virus have been used to knockdown levels of mutated superoxide dismutase 1 (SOD1) in the G93A SOD1 mouse model of familial amyotrophic lateral sclerosis (fALS) to result in beneficial therapeutic outcomes. This chapter describes the design, production, and titration of lentivirus and adeno-associated virus capable of mediating SOD1 knockdown in vivo. The delivery of the virus to the spinal cord directly, through intraspinal injection, or indirectly, through intramuscular injection, is also described, as well as the methods pertaining to the analysis of spinal cord transduction, SOD1 silencing, and determination of motor neuron protection.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bruijn, L.I., Miller, T.M. and Cleveland, D.W. (2004) Unravelling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27, 723–749.
Dykxhoorn, D.M., Novina, C.D. and Sharp, P.A. (2003) Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 4, 457–467.
Saito, Y., Yokota, T., Mitani, T., Ito, K., Anzai, M., Miyagishi, M., Taira, K. and Mizusawa, H. (2005) Transgenic small interfering RNA halts amyotrophics lateral sclerosis in a mouse model. J. Biol. Chem. 280, 42826–42830.
Smith, R.A., Miller, T.M., Yamanaka, K., Monia, B.P., Condon, T.P., Hung, G., Lobsiger, C.S., Ward, C.M., McAlonis-Downes, M., Wei, H., Wancewicz, E.V., Bennett, C.F. and Cleveland, D.W. (2006) Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116, 2290–2296.
Zamore, P.D., Tuschl, T., Sharp, P.A. and Bartel, D.P. (2000) RNAi: double stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101, 25–33.
Ralph, G.S., Radcliffe, P.A., Day, D.M., Carthy, J.M., Leroux, M.A., Lee, D.C., Wong, L.F., Bilsland, L.G., Greensmith, L., Kingsman, S.M., Mitrophanous, K.A., Mazarakis, N.D. and Azzouz, M. (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med, 11, 429–433.
Raoul, C., Abbas-Terki, T., Bensadoun, J.C., Guillot, S., Haase, G., Szulc, J., Henderson, C.E. and Aebischer, P. (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 11, 423–428.
Boillee, S., Vande Velde, C. and Cleveland, D.W. (2006) ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52, 39–59.
Miller, T.M., Kaspar, B.K., Kops, G.J., Yamanaka, K., Christian, L.J., Gage, F.H. and Cleveland, D.W. (2005) Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann. Neurol. 57, 773–776.
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W.S. and Khvorova, A. (2004) Rational siRNA design for RNA interference. Nat. Biotechnol. 22, 326–330.
Saetrom, P. and Snove, O.J. (2004) A comparison of siRNA efficacy predictors. Biochem. Biophys. Res. Commun. 321, 247–253.
Takasaki, S., Kotani, S. and Konagaya, A. (2004) An effective method for selecting siRNA target sequences in mammalian cells. Cell Cycle 3, 790–795.
Ui-Tei, K., Naito, Y., Takahashi, F., Haraguchi, T., Ohki-Hamazaki, H., Juni, A., Ueda, R. and Saigo, K. (2004) Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 32, 936–948.
Hsieh, A.C., Bo, R., Manola, J., Vazquez, F., Bare, O., Khvorova, A., Scaringe, S. and Sellers W.R. (2004) A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res. 32, 893–901.
Amarzguioui, M. and Prydz, H. (2004) An algorithm for selection of functional siRNA sequences. Biochem. Biophys. Res. Commun. 316, 1050–1058.
Taxman, D.J., Livingstone, L.R., Zhang, J., Conti, B.J., Iocca, H.A., Williams, K.L., Lich, J.D., Ting, J.P. and Reed, W. (2006) Criteria for effective design, construction, and gene knockdown by shRNA vectors. BMC Biotechnol. 6, 7.
Graham, F.L., Smiley, J., Russell, W.C. and Nairn, R. (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59–74.
Grimm, D., Kay, M.A. and Kleinschmidt, J.A. (2003) Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7, 839–850.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Towne, C., Aebischer, P. (2009). Lentiviral and Adeno-Associated Vector-Based Therapy for Motor Neuron Disease Through RNAi. In: Rondinone, C., Reidhaar-Olson, J. (eds) Therapeutic Applications of RNAi. Methods in Molecular Biology™, vol 555. Humana Press. https://doi.org/10.1007/978-1-60327-295-7_7
Download citation
DOI: https://doi.org/10.1007/978-1-60327-295-7_7
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-294-0
Online ISBN: 978-1-60327-295-7
eBook Packages: Springer Protocols